NCT07244874尚未招募2 期
A Single Arm, Phase II Study of Sacituzumab Tirumotecan（Sac-TMT） Combined With Toripalimab for First-line Treatment of PD-L1 Positive Unresectable Locally Advanced/Metastatic Triple Negative Breast Cancer (a/mTNBC)
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 41
- 主要终点
- Objective response rate (ORR)
研究概览
简要总结
This study is aimed to evaluate the efficacy and safety of Sacituzumab Tirumotecan combined with Toripalimab for first-line treatment of PD-L1 positive unresectable Locally Advanced/metastatic triple negative breast cancer (a/mTNBC).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Female patients with breast cancer aged >= 18 years.
- •Based on the pathological report of the latest biopsy or other pathological specimens, the histology and/or cytology are confirmed as invasive breast cancer, and the following conditions are met: a) Pathological classification: ER <= 10%, PR <= 10%; HER2 negative (IHC 0, 1+, 2+and FISH negative); Note: Subjects with initial histopathological diagnosis of HR>10% or HER2+breast cancer and recent pathological findings of metastatic lesions meeting the above conditions are allowed to be included in the study. b) Tumor staging: locally advanced, recurrent, or metastatic tumors that cannot be surgically removed; Note: Patients who have received perioperative treatment in the past are required to have a disease-free survival period of >= 6 months;
- •ECOG overall state is 0-
- •Have not received systematic treatment for advanced diseases.
- •There are tissue samples available for PD-L1 testing, and the test results show PD-L1 positive: CPS >=
- •The expected survival period is not less than 3 months.
- •According to the RECIST v1.1 standard, there must be at least one measurable lesion present.
- •Having sufficient organ and bone marrow function (without receiving blood transfusion, recombinant human thrombopoietin or colony-stimulating factor therapy within 2 weeks prior to the first administration), defined as follows: a) Blood routine: neutrophil count (NEUT #) >= 1.5 × 10^9/L; platelet count (PLT) >= 100 × 10^9/L; hemoglobin >= 90g/dL; b) Liver function: Aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP) <= 2.5 x upper limit of normal (ULN); Total bilirubin (TBIL) <= 1.5 × ULN; For patients with liver metastases, ALT and AST should be <= 5 × ULN, and TBIL should be <= 2 × ULN; For patients with liver or bone metastases, ALP <= 5 × ULN; c) Renal function: creatinine clearance rate (Ccr) >= 60ml/min; d) Coagulation function: International normalized ratio (INR), activated partial thromboplastin time (APTT), and prothrombin time (PT) <= 1.5 × ULN; e) Cardiac function: Echocardiography (ECHO) or multi circuit controlled acquisition (MUGA) scan shows left ventricular ejection fraction (LVEF) >= 50%;
- •Patients must recover from all toxicity caused by previous treatment (to <= grade 1, evaluated based on CTCAE 5.0, or meet the inclusion criteria of the protocol), except for hair loss and vitiligo.
- •Patients with negative serum pregnancy test results and those with fertility potential must agree to use effective non hormonal contraceptive methods during treatment and for at least 6 months after the last use of the test drug.
- •Voluntarily joining this study, signing informed consent, having good compliance, and willing to cooperate with follow-up.
排除标准
- •Patients with central nervous system metastases.
- •Received radiotherapy, endocrine therapy, chemotherapy, surgical treatment (excluding local puncture or biopsy) or molecular targeted therapy during the recurrence/metastasis stage.
- •Participated in clinical trials of other drugs within 4 weeks prior to enrollment.
- •Previously treated with anti-PD-1, anti-PD-L1, anti-PD-L-2, or anti-CTLA-4 antibodies, or any other antibodies or drugs that specifically target T cell co stimulatory or checkpoint pathways.
- •Previously used treatment targeting TROP2 and/or topoisomerase I inhibitors.
- •Other malignant tumors within the past 5 years, excluding cured cervical carcinoma in situ, basal cutaneous carcinoma, or squamous cell carcinoma of the skin.
- •Known history of allergies to the drugs and their components in this protocol.
- •Human immunodeficiency virus (HIV) test is positive or there is a history of acquired immunodeficiency syndrome (AIDS); Known active syphilis infection.
- •History of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation.
- •Vaccination with live vaccine within 30 days prior to the first study administration.
- •History of (non infectious) interstitial lung disease (ILD) or non infectious pneumonia requiring steroid treatment, current ILD or non infectious pneumonia, or suspected ILD or non infectious pneumonia that cannot be excluded by imaging examination during screening; Clinical severe lung damage caused by concurrent lung diseases, including but not limited to any underlying lung disease (such as pulmonary embolism, severe asthma, severe chronic obstructive pulmonary disease, restrictive lung disease, pleural effusion, etc. within 3 months prior to administration) or any autoimmune, connective tissue, or inflammatory disease that may affect the lungs (i.e. rheumatoid arthritis, Sjogren's syndrome, sarcoidosis, etc.), or previous total pneumonectomy.
- •Patients with active autoimmune diseases that need systematic treatment in the past two years (hormone replacement therapy is not considered as systematic treatment, such as type I diabetes, hypothyroidism requiring only thyroid hormone replacement therapy, adrenal or pituitary insufficiency requiring only physiological dose of glucocorticoid hormone replacement therapy).
- •Active infections requiring systemic treatment within 2 weeks prior to the first administration.
- •ccording to the investigator's judgment, there are concomitant diseases that seriously endanger the patient's safety or affect the patient's completion of the study, including but not limited to high blood pressure beyond the control of drugs, serious diabetes, active infection, etc.
- •There is a recorded history of severe dry eye syndrome, severe meibomian gland disease and/or blepharitis, or corneal diseases that hinder delayed corneal healing.
- •Pregnant and lactating female patients, female patients with fertility and positive baseline pregnancy test results, and female patients of childbearing age who are unwilling to take effective contraceptive measures during the trial drug treatment period and the last 6 months of medication..
- •The researchers believe that the patient is not suitable to participate in any other circumstances of this study.
研究组 & 干预措施
Sacituzumab Tirumotecan + Toripalimab
Experimental
干预措施: Sacituzumab tirumotecan (Drug)
Sacituzumab Tirumotecan + Toripalimab
Experimental
干预措施: Toripalimab (Drug)
结局指标
主要结局
Objective response rate (ORR)
时间窗: Up to approximately 15 months
次要结局
- Progression-Free-Survival(Up to approximately 15 moths)
- Duration of Response(Up to approximately 15 months)
- Overall Survival(Up to approximately 4 years)
- adverse events(Up to approximately 15 months)
研究者
相似试验
尚未招募
不适用
Sacituzumab Tirumotecan (Sac-TMT) Plus Bevacizumab in 3rd Generation EGFR-TKI Treated Advanced EGFR-mutant Nonsquamous NSCLC With Brain MetastasisLung CancerNCT07197008Li-kun Chen50
招募中
2 期
Sacituzumab Tirumotecan and Toripalimab in the First-line Treatment of HNSCCNCT07088211Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University39
尚未招募
2 期
Efficacy and Safety of Sacituzumab Tirumotecan (SKB264) in Combination With Toripalimab in Patients With Initially Unresectable Stage III NSCLCNon Small Cell Lung Cancer (Stage III)NCT06706219Hunan Province Tumor Hospital50
招募中
不适用
Sacituzumab Tirumotecan Combined With Immunotherapy in Advanced Thyroid CancerNCT07068542Zhejiang Provincial People's Hospital94
招募中
2 期
Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC)NCT07179783Tianjin Medical University Second Hospital28